{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,4,26]],"date-time":"2025-04-26T04:07:22Z","timestamp":1745640442809,"version":"3.40.4"},"reference-count":26,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,4,25]]},"DOI":"10.7759\/cureus.82981","type":"journal-article","created":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T14:14:38Z","timestamp":1745590478000},"source":"Crossref","is-referenced-by-count":0,"title":["Clinical Impact of Radiotherapy in Steroid-Refractory Graves' Orbitopathy"],"prefix":"10.7759","author":[{"given":"Elizabeth","family":"Escobar Peralta","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jos\u00e9 Manuel","family":"Garc\u00eda Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christian Helbert H","family":"Ordo\u00f1ez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mar\u00eda Yisel","family":"Bautista Hern\u00e1ndez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2020.101388","article-title":"Graves' disease: clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy","volume":"34","author":"Antonelli A","year":"2020","unstructured":"Antonelli A, Fallahi P, Elia G, et al.. Graves' disease: clinical manifestations, immune pathogenesis (cytokines and chemokines) and therapy. Best Pract Res Clin Endocrinol Metab. 2020, 34:101388. 10.1016\/j.beem.2020.101388","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2020.615993","article-title":"Epidemiology, natural history, risk factors, and prevention of Graves\u2019 orbitopathy","volume":"11","author":"Bartalena L","year":"2020","unstructured":"Bartalena L, Piantanida E, Gallo D, Lai A, Tanda ML. Epidemiology, natural history, risk factors, and prevention of Graves\u2019 orbitopathy. Front Endocrinol (Lausanne). 2020, 11:615993. 10.3389\/fendo.2020.615993","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref3","article-title":"The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota","volume":"92","author":"Bartley GB","year":"1994","unstructured":"Bartley GB. The epidemiologic characteristics and clinical course of ophthalmopathy associated with autoimmune thyroid disease in Olmsted County, Minnesota. Trans Am Ophthalmol Soc. 1994, 92:477-588.","journal-title":"Trans Am Ophthalmol Soc"},{"key":"ref4","doi-asserted-by":"crossref","DOI":"10.1001\/jama.1993.03500040045034","article-title":"Smoking and risk of Graves' disease","volume":"269","author":"Prummel MF","year":"1993","unstructured":"Prummel MF, Wiersinga WM. Smoking and risk of Graves' disease. JAMA. 1993, 269:479-82.","journal-title":"JAMA"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1111\/joim.13524","article-title":"Current concepts regarding Graves' orbitopathy","volume":"292","author":"Bartalena L","year":"2022","unstructured":"Bartalena L, Tanda ML. Current concepts regarding Graves' orbitopathy. J Intern Med. 2022, 292:692-716. 10.1111\/joim.13524","journal-title":"J Intern Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-021-05456-x","article-title":"The risk factors for Graves' ophthalmopathy","volume":"260","author":"Cao J","year":"2022","unstructured":"Cao J, Su Y, Chen Z, Ma C, Xiong W. The risk factors for Graves' ophthalmopathy. Graefes Arch Clin Exp Ophthalmol. 2022, 260:1043-54. 10.1007\/s00417-021-05456-x","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1038\/s41574-019-0311-6","article-title":"Selenium in thyroid disorders - essential knowledge for clinicians","volume":"16","author":"Winther KH","year":"2020","unstructured":"Winther KH, Rayman MP, Bonnema SJ, Heged\u00fcs L. Selenium in thyroid disorders - essential knowledge for clinicians. Nat Rev Endocrinol. 2020, 16:165-76. 10.1038\/s41574-019-0311-6","journal-title":"Nat Rev Endocrinol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2017.0430","article-title":"High serum cholesterol is a novel risk factor for Graves\u2019 orbitopathy: results of a cross-sectional study","volume":"28","author":"Sabini E","year":"2018","unstructured":"Sabini E, Mazzi B, Profilo MA, et al.. High serum cholesterol is a novel risk factor for Graves\u2019 orbitopathy: results of a cross-sectional study. Thyroid. 2018, 28:386-94. 10.1089\/thy.2017.0430","journal-title":"Thyroid"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1210\/en.2017-00528","article-title":"TSH\/IGF-1 receptor cross-talk rapidly activates extracellular signal-regulated kinases in multiple cell types","volume":"158","author":"Krieger CC","year":"2017","unstructured":"Krieger CC, Perry JD, Morgan SJ, Kahaly GJ, Gershengorn MC. TSH\/IGF-1 receptor cross-talk rapidly activates extracellular signal-regulated kinases in multiple cell types. Endocrinology. 2017, 158:3676-83. 10.1210\/en.2017-00528","journal-title":"Endocrinology"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1062045","article-title":"A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves' orbitopathy","volume":"14","author":"Cui X","year":"2023","unstructured":"Cui X, Wang F, Liu C. A review of TSHR- and IGF-1R-related pathogenesis and treatment of Graves' orbitopathy. Front Immunol. 2023, 14:1062045. 10.3389\/fimmu.2023.1062045","journal-title":"Front Immunol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1530\/EJE-21-0479","article-title":"The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy","volume":"185","author":"Bartalena L","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L, et al.. The 2021 European Group on Graves' orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves' orbitopathy. Eur J Endocrinol. 2021, 185:G43-67. 10.1530\/EJE-21-0479","journal-title":"Eur J Endocrinol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2021.12.004","article-title":"2022 update on clinical management of Graves disease and thyroid eye disease","volume":"51","author":"Hoang TD","year":"2022","unstructured":"Hoang TD, Stocker DJ, Chou EL, Burch HB. 2022 update on clinical management of Graves disease and thyroid eye disease. Endocrinol Metab Clin North Am. 2022, 51:287-304. 10.1016\/j.ecl.2021.12.004","journal-title":"Endocrinol Metab Clin North Am"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1016\/s0360-3016(01)01699-6","article-title":"Long-term results of irradiation for patients with progressive Graves' ophthalmopathy","volume":"51","author":"Marquez SD","year":"2001","unstructured":"Marquez SD, Lum BL, McDougall IR, Katkuri S, Levin PS, MacManus M, Donaldson SS. Long-term results of irradiation for patients with progressive Graves' ophthalmopathy. Int J Radiat Oncol Biol Phys. 2001, 51:766-74. 10.1016\/s0360-3016(01)01699-6","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2003.12.054","article-title":"Orbital irradiation for Graves' ophthalmopathy: is it safe? A long-term follow-up study","volume":"111","author":"Wakelkamp IM","year":"2004","unstructured":"Wakelkamp IM, Tan H, Saeed P, et al.. Orbital irradiation for Graves' ophthalmopathy: is it safe? A long-term follow-up study. Ophthalmology. 2004, 111:1557-62. 10.1016\/j.ophtha.2003.12.054","journal-title":"Ophthalmology"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1016\/s0161-6420(01)00632-7","article-title":"A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy","volume":"108","author":"Gorman CA","year":"2001","unstructured":"Gorman CA, Garrity JA, Fatourechi V, et al.. A prospective, randomized, double-blind, placebo-controlled study of orbital radiotherapy for Graves' ophthalmopathy. Ophthalmology. 2001, 108:1523-34. 10.1016\/s0161-6420(01)00632-7","journal-title":"Ophthalmology"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1080\/1744666X.2021.1997591","article-title":"How suitable is intravenous tocilizumab for the treatment of Graves' ophthalmopathy?","volume":"17","author":"Mej\u00eda Gonz\u00e1lez MA","year":"2021","unstructured":"Mej\u00eda Gonz\u00e1lez MA, Carbone J. How suitable is intravenous tocilizumab for the treatment of Graves' ophthalmopathy?. Expert Rev Clin Immunol. 2021, 17:1151-3. 10.1080\/1744666X.2021.1997591","journal-title":"Expert Rev Clin Immunol"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1614949","article-title":"Teprotumumab for thyroid-associated ophthalmopathy","volume":"376","author":"Smith TJ","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG, et al.. Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med. 2017, 376:1748-61. 10.1056\/NEJMoa1614949","journal-title":"N Engl J Med"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1097\/MED.0000000000000097","article-title":"Immunotherapy for Graves' ophthalmopathy","volume":"21","author":"Salvi M","year":"2014","unstructured":"Salvi M. Immunotherapy for Graves' ophthalmopathy. Curr Opin Endocrinol Diabetes Obes. 2014, 21:409-14. 10.1097\/MED.0000000000000097","journal-title":"Curr Opin Endocrinol Diabetes Obes"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2007.11.016","article-title":"Vitreous penetration of orally administered valacyclovir","volume":"145","author":"Huynh TH","year":"2008","unstructured":"Huynh TH, Johnson MW, Comer GM, Fish DN. Vitreous penetration of orally administered valacyclovir. Am J Ophthalmol. 2008, 145:682-6. 10.1016\/j.ajo.2007.11.016","journal-title":"Am J Ophthalmol"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1007\/s00066-002-0901-3","article-title":"[Functional and molecular aspects of anti-inflammatory effects of low-dose radiotherapy]","volume":"178","author":"R\u00f6del F","year":"2002","unstructured":"R\u00f6del F, Kamprad F, Sauer R, Hildebrandt G. [Functional and molecular aspects of anti-inflammatory effects of low-dose radiotherapy]. Strahlenther Onkol. 2002, 178:1-9. 10.1007\/s00066-002-0901-3","journal-title":"Strahlenther Onkol"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1007\/s00417-016-3280-7","article-title":"Efficacy of combined orbital radiation and systemic steroids in the management of Graves' orbitopathy","volume":"254","author":"Kim JW","year":"2016","unstructured":"Kim JW, Han SH, Son BJ, Rim TH, Keum KC, Yoon JS. Efficacy of combined orbital radiation and systemic steroids in the management of Graves' orbitopathy. Graefes Arch Clin Exp Ophthalmol. 2016, 254:991-8. 10.1007\/s00417-016-3280-7","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1089\/105072502753600223","article-title":"Orbital radiotherapy for Graves' ophthalmopathy","volume":"12","author":"Bartalena L","year":"2002","unstructured":"Bartalena L, Marcocci C, Tanda ML, Rocchi R, Mazzi B, Barbesino G, Pinchera A. Orbital radiotherapy for Graves' ophthalmopathy. Thyroid. 2002, 12:245-50. 10.1089\/105072502753600223","journal-title":"Thyroid"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.1007\/BF03347309","article-title":"Lack of effect of hexarelin on TRH-induced TSH response in normal adult man","volume":"21","author":"Arosio M","year":"1998","unstructured":"Arosio M, Casati G, Biella O, Porretti S, Imbimbo BP, Faglia G. Lack of effect of hexarelin on TRH-induced TSH response in normal adult man. J Endocrinol Invest. 1998, 21:239-44. 10.1007\/BF03347309","journal-title":"J Endocrinol Invest"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1007\/s11845-016-1542-3","article-title":"Radiotherapy for the treatment of thyroid eye disease-a prospective comparison: Is orbital radiotherapy a suitable alternative to steroids?","volume":"186","author":"Grassi P","year":"2017","unstructured":"Grassi P, Strianese D, Piscopo R, Pacelli R, Bonavolont\u00e0 G. Radiotherapy for the treatment of thyroid eye disease-a prospective comparison: Is orbital radiotherapy a suitable alternative to steroids?. Ir J Med Sci. 2017, 186:647-52. 10.1007\/s11845-016-1542-3","journal-title":"Ir J Med Sci"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.3390\/diseases13020061","article-title":"Orbital radiotherapy for Graves\u2019 ophthalmopathy: single institutional experience of efficacy and safety","volume":"13","author":"La Rocca M","year":"2025","unstructured":"La Rocca M, Leonardi BF, Lo Greco MC, et al.. Orbital radiotherapy for Graves\u2019 ophthalmopathy: single institutional experience of efficacy and safety. Diseases. 2025, 13:10.3390\/diseases13020061","journal-title":"Diseases"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2009-0376","article-title":"Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis","volume":"94","author":"Stiebel-Kalish H","year":"2009","unstructured":"Stiebel-Kalish H, Robenshtok E, Hasanreisoglu M, Ezrachi D, Shimon I, Leibovici L. Treatment modalities for Graves' ophthalmopathy: systematic review and metaanalysis. J Clin Endocrinol Metab. 2009, 94:2708-16. 10.1210\/jc.2009-0376","journal-title":"J Clin Endocrinol Metab"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/354983-clinical-impact-of-radiotherapy-in-steroid-refractory-graves-orbitopathy","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,25]],"date-time":"2025-04-25T14:14:39Z","timestamp":1745590479000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/354983-clinical-impact-of-radiotherapy-in-steroid-refractory-graves-orbitopathy"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,25]]},"references-count":26,"URL":"https:\/\/doi.org\/10.7759\/cureus.82981","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2025,4,25]]}}}